7-(tetrahydro-pyran-4-ylamino)-[1,6]naphthyridine-2-carboxylic acid [(S)-(3-fluoro-phenyl)-(1-methyl-1H-pyrazol-4-yl)-methyl]-amide | 1574395-63-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 7-(tetrahydro-pyran-4-ylamino)-[1,6]naphthyridine-2-carboxylic acid [(S)-(3-fluoro-phenyl)-(1-methyl-1H-pyrazol-4-yl)-methyl]-amide
• 英文别名: N-[(S)-(3-fluorophenyl)-(1-methylpyrazol-4-yl)methyl]-7-(oxan-4-ylamino)-1,6-naphthyridine-2-carboxamide
• CAS: 1574395-63-3
• 化学式: C₂₅H₂₅FN₆O₂
• 分子量: 460.511
• InChiKey: IBZNBXHJWJLZKM-DEOSSOPVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  94
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• SERINE/THREONINE KINASE INHIBITORS
  申请人：Blake Jim

  公开号：US20140066453A1

  公开（公告）日：2014-03-06

  Compounds having the formula I wherein R 2 , X and Z as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.

  具有公式I的化合物，其中R2、X和Z如本文所定义，是ERK激酶的抑制剂。还披露了用于治疗过度增殖性疾病的组合物和方法。
• US9388171B2
  申请人：——

  公开号：US9388171B2

  公开（公告）日：2016-07-12
• [EN] SERINE/THREONINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE|DISEASES<br/>[FR] INHIBITEURS DE SÉRINE/THRÉONINE KINASE POUR LE TRAITEMENT DE MALADIES HYPERPROLIFÉRATIVES
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014036015A1

  公开（公告）日：2014-03-06

  Compounds having the formula I are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating adenoma, bladder cancer, brain cancer, breast cancer, colon cancer, epidermal carcinoma, follicular carcinoma, cancer of the genitourinary tract, glioblastoma, Hodgkin's disease, head and neck cancers, hepatoma, keratoacanthoma, kidney cancer, large cell carcinoma, leukemias, lung adenocarcinoma, lung cancer, lymphoid disorders, melanoma and non-melanoma skin cancer, myelodysplasia syndrome, neuroblastoma, non-Hodgkins lymphoma, ovarian cancer, papillary carcinoma, pancreatic cancer, prostate cancer, rectal cancer, sarcoma, small cell carcinoma, testicular cancer, tetracarcinomas, thyroid cancer, and undifferentiated carcinoma.